Empagliflozin/linagliptin Combo Tablet Shows Sustained Reduction in BG

Boehringer Ingelheim, and Eli Lilly & Co. have presented results from a 52-week Phase III study demonstrating sustained efficacy of the investigational empagliflozin/linagliptin combination tablet in adults with T2DM already taking metformin and in those who were previously untreated. The results, presented during the 50th Annual Meeting of the European Association for the Study of Diabetes, also confirmed the safety profile of the combination tablet.